Oncolytics Biotech announces voting results from annual meeting

SAN DIEGO - Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), whose stock has delivered an impressive 56% return year-to-date according to InvestingPro data, reported Monday that shareholders elected all eight director nominees at its Annual General Meeting held on Friday, August 8, 2025.

The clinical-stage immunotherapy company, which is developing pelareorep, saw 37.42% of its issued and outstanding common shares represented at the meeting either in person or by proxy. InvestingPro analysis indicates strong market confidence, with 5 analysts recently revising their earnings estimates upward and projecting profitability this year.

All director nominees received strong support, with approval ratings ranging from 80.45% to 91.64%. Jared Kelly received the highest approval at 91.64%, while Jonathan Rigby received 80.45% of votes cast.

Shareholders also approved additional resolutions, including fixing the number of directors at eight and appointing auditors for the coming year.

Oncolytics Biotech is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors for metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA. The company is also exploring treatments for other gastrointestinal tumors. With a solid current ratio of 1.95 and moderate debt levels, the company appears well-positioned to fund its clinical development programs. Unlock more insights about ONCY’s financial health with InvestingPro, which offers 12 additional investment tips for this stock.

According to the press release statement, pelareorep has shown promising results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer.

The company stated that detailed voting results will be filed on SEDAR.

In other recent news, BeiGene reported its second-quarter financial results, revealing that the company’s revenue exceeded analyst expectations. However, earnings for the same period fell short of estimates. This mixed financial performance highlights a divergence between the company’s revenue generation and profitability. Meanwhile, Oncolytics Biotech announced its decision to voluntarily delist its common shares from the Toronto Stock Exchange, effective August 22, 2025. The company will continue its listing on Nasdaq, citing a strategic shift towards a stronger U.S. market focus as the reason for this move. These developments reflect ongoing strategic and financial adjustments within both companies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.